Bioequivalence Study,
Conditions
Interventions
Generic febuxostat 80 mg film-
Each tablet contains 80 mg of febuxostat.,Feburic® 80 mg,
Reg. No. 1B 2/58 (N),
manufactured by Patheon France,
40 Boulevard de Champaret,
38300 Bourgoin Jallieu,
France
and packed and released by Interthai Pharmaceutical
Manufacturing Ltd.,
Bangkok,
Thailand. Each tablet contains
80 mg of febuxostat.
Active Comparator Drug,Active Comparator Drug
Test (T) Generic febuxostat 80 mg film-
,Reference (R): Febuxostat 80 mg film-
Feburic® 80 mg,
Sponsors
International Bio Service Co.,Ltd.
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Healthy Thai male or female subjects between the ages of 18 to 55 years. 2.Body mass index between 18.0 to 30.0 kg/m2 3.Normal laboratory values, including vital signs and physical examination, for all parameters in clinical laboratory tests at screening. Any abnormalities from the normal or reference range will be carefully considered clinically relevant by the physician as individual cases, documented in study files prior to enrolling the subject in this study. 4.Non-pregnant woman (negative pregnancy test) and not currently breast feeding. 5.Female subjects abstain from either hormonal methods of contraception (including oral or transdermal contraceptives, injectable progesterone, progestin subdermal implants, progesterone-releasing IUDs, postcoital contraceptive methods) or hormone replacement therapy for at least 28 days prior to check-in in Period 1. injectable contraceptives e.g. Depo-Provera® will be discontinued at least 6 months prior to check-in in Period 1. Subjects agree to use acceptable non-hormonal contraceptive methods such as condom, diaphragm, foams, jellies, or abstinence for at least 14 days prior to check-in in Period 1 until 7 days after the end of study in Period 2. Female subjects of non-childbearing potential must meet at least one of the following criteria prior to check-in in Period 1:  Postmenopausal for at least 1 year or  Surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) at least 6 months 6.Male subjects who are willing or able to use effective contraceptive e.g. condom or abstinence after admission in Period 1 until 7 days after the end of study in Period 2. 7.Have voluntarily given written informed consent (signed and dated) by the subject prior to participating in this study 8.
Exclusion criteria
Exclusion criteria: 1.History of allergic reaction or hypersensitivity to febuxostat or to any of the excipients 2.History or evidence of clinically significant renal, hepatic, gastrointestinal, hematological (e.g. anemia), endocrine (e.g. hyper-/hypothyroid, diabetes), pulmonary or respiratory (e.g. asthma), cardiovascular, psychiatric (e.g. depression), neurologic (e.g. convulsant), allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) or any significant ongoing chronic medical illness 3.Have high risk for coronavirus infection based on risk assessment questionnaire or diagnosed as confirmed case of COVID-19 4.History or evidence of ischaemic heart disease, myocardial infarction, congestive heart failure or atherosclerotic disease 5.History or evidence of gout 6.History or evidence of Lesch-Nyhan syndrome 7.History or evidence of thyroid disorders 8.History or evidence of organ transplant 9.History of problems with swallowing tablet or capsule 10.History or evidence of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption 11.History of sensitivity to heparin or heparin-induced thrombocytopenia 12.Any condition possibly affecting drug absorption e.g. gastrectomy, enterectomy, gastritis or duodenal or gastric ulceration other than appendectomy 13.History of preceding diarrhea within 24 hours prior to check-in in each period 14.History or evidence of drug addict or investigation with urine sample shows a positive test for drug of abuse (morphine, marijuana or methamphetamine) 15.Investigation with blood sample shows hyperuricaemia, a serum urate level greater than 6.0 mg/dL in women and 7.0 mg/dL in men at screening laboratory test. 16.12-lead ECG demonstrating QTc >450 msec, a QRS interval >120 msec or with an abnormality considered clinically significant at screening. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG will be repeated two more times and the average of the three QTc or QRS values will be used to determine the subject’s eligibility. 17.Investigation with blood sample shows positive test for HBsAg 18.Abnormal liver function, ≥1.5 times of upper normal limit of reference range for ALT, AST or bilirubin levels at screening laboratory test 19.Have renal creatinine clearance (Clcr) <30 mL/min based on serum creatinine results, using glomerular filtration rate (GFR; Cockcroft-Gault formula), at the screening laboratory test. 20.History or evidence of habitual use of tobacco or nicotine containing products and cannot abstain for at least 48 hours prior to check-in in Period 1and continued for entire duration of the study 21.History or evidence of alcoholism or harmful use of alcohol (less than 2 years) i.e., alcohol consumption of more than 14 standard drinks per week for men and 7 standard drinks per week for women (A standard drink is defined as 360 mL of beer or 150 mL of wine or 45 mL of 40% distilled spirits, such as rum, whisky, brandy etc.) 22.History or evidence of alcohol consumption or alcohol-containing products and cannot abstain for at least 48 hours prior to check-in in Period 1 and continued for entire duration of the study or alcohol breath test shows positive result In case of alcohol breath test result represents t
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Febuxostat plasma concentration 0-36 hrs Cmax, AUC0-tlast and AUC0-∞ | — |
Secondary
| Measure | Time frame |
|---|---|
| Febuxostat plasma concentration 0-36 hrs Tmax, t1/2, AUC0-tlast/AUC0-∞, AUC%extrapolate, λz and MRT | — |
Countries
Thailand
Contacts
Public ContactPorranee Puranajoti
International Bio Service Co.,Ltd
Outcome results
None listed